646502-54-7
Chemical Structure
Mc-Phe-Lys-PAB-MMAE
- CAS No.: 646502-54-7
- Formula:C72H106N10O14
- Molecular Weight:1335.67
IUPAC Name: 4-((S)-6-amino-2-((S)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)-3-phenylpropanamido)hexanamido)benzyl ((S)-1-(((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-y
InChIKey: FRPQRQTYROMYFD-RONWFJSWSA-N
SMILES: CN([C@@H]([C@@H](C)CC)[C@H](OC)CC(N1[C@H]([C@H](OC)[C@@H](C)C(N[C@H](C)[C@@H](O)C2=CC=CC=C2)=O)CCC1)=O)C([C@H](C(C)C)NC([C@H](C(C)C)N(C(OCC3=CC=C(NC([C@H](CCCCN)NC([C@H](CC4=CC=CC=C4)NC(CCCCCN5C(C=CC5=O)=O)=O)=O)=O)C=C3)=O)C)=O)=O
Biological Activity: Mc-Phe-Lys-PAB-MMAE (Compound 2) is a drug-linker conjugate for ADC, and can be used for synthesis of ADCs[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Mc-Phe-Lys-PAB-MMAE | Mc-Phe-Lys-PAB-MMAE (Compound 2) is a drug-linker conjugate for ADC, and can be used for synthesis of ADCs. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MC-Val-Cit-PAB-MMAF | 99.25% | MC-Val-Cit-PAB-MMAF (Vc-MMAF) is a drug-linker conjugate for ADC by using the tubulin inhibitor, MMAF (HY-15579), linked via cathepsin cleavable MC-Val-Cit-PAB (HY-78738). MC-Val-Cit-PAB-MMAF shows antitumor activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MC-Gly-Gly-Phe-Gly-PAB-MMAE | 99.23% | MC-Gly-Gly-Phe-Gly-PAB-MMAE (Compound SMP-81641) is a control targeted linker-agent conjugate. MC-Gly-Gly-Phe-Gly-PAB-MMAE can be used in tumor research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Mc-Alanyl-Alanyl-Asparagine-PAB-MMAE | 99.82% | Mc-Alanyl-Alanyl-Asparagine-PAB-MMAE (compound S6) is a potent anticancer agent, which can be specific activated by tumor microenvironment. Mc-Alanyl-Alanyl-Asparagine-PAB-MMAE can suppress tumor growth in mice (extracted from patent CN104147612A). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MC-VA-PABC-MMAE | 99.93% | MC-VA-PABC-MMAE is a agent-linker conjugate for ADC. MC-VA-PABC-MMAE contains the ADCs linker (peptide MC-VA-PABC) and a potent tubulin polymerization inhibitor MMAE (HY-15162). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MC-EVCit-PAB-MMAE | 99.67% | MC-EVCit-PAB-MMAE (Linker-Payload 11) is a drug-linker conjugates for ADC. MC-EVCit-PAB-MMAE contains the ADCs linker (MC-EVCit-PAB) and a potent tubulin polymerization inhibitor MMAE (HY-15162). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
VcMMAE (Standard) | 99.95% | VcMMAE (Standard) is the analytical standard of VcMMAE. This product is intended for research and analytical applications. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GGFG-PAB-MMAE | 99.33% | GGFG-PAB-MMAE (Comp 58054-1) is a drug-linker conjugate for ADC. GGFG-PAB-MMAE contains the ADC linker (GGFG-PAB) and a potent tubulin polymerization inhibitor MMAE (HY-15162). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Mal-GGFG-PAB-MMAE | 99.96% | Mal-GGFG-PAB-MMAE (Compound 8) is a drug-linker conjugate, which is composed of the mitotic inhibitor MMAE (HY-15162) and the linker Mal-GGFG-PAB. Mal-GGFG-PAB-MMAE can be used for synthesis of ADCs. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Mc-Pro-PAB-MMAE | 99.16% | Mc-Pro-PAB-MMAE is a Drug-Linker Conjugate for ADC. Mc-Pro-PAB-MMAE consists of Monomethyl auristatin E (HY-15162) and a linker. Mc-Pro-PAB-MMAE can be used for synthesis of ADCs. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Mal-Val-Lys-PAB-MMAE | Mal-Val-Lys-PAB-MMAE is a drug-linker conjugate for ADC. Mal-Val-Lys-PAB-MMAE consists of a Tubulin inhibitor (MMAE) (HY-15162) and a linker (Mal-Val-Lys-PAB). Mal-Val-Lys-PAB-MMAE can be used for synthesis of ADCs. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
